Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study

Abstract Introduction Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder that impacts children aged ≤ 16 years. This study evaluated the efficacy and safety of firsekibart, a fully human anti-IL-1β monoclonal antibody, in children with active sJIA. Methods This multicenter...

Descrición completa

Detalles Bibliográficos

Principais autores:	Caifeng Li, Junmei Zhang, Haiguo Yu, Meiping Lu, Sirui Yang, Cuihua Liu, Ping Zeng, Bo Zhao, Xiaoqing Li, Wenjie Zheng, Yue Du, Wei Zhang, Zhihui Li, Xiufen Hu, Jianming Lai, Qian Xu, Xu Zhang, Xianyang Wang, Palasaiti Adili, Wei Qu
Formato:	Artigo
Idioma:	Inglês
Publicado:	Adis, Springer Healthcare 2026-03-01
Series:	Rheumatology and Therapy
Assuntos:	Firsekibart Interleukin-1β (IL-1β) Phase 2 study Systemic juvenile idiopathic arthritis
Acceso en liña:	https://doi.org/10.1007/s40744-026-00830-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!